Cerebrolysin is a porcine-brain-derived mixture
Cerebrolysin is not one defined peptide. It is an injectable mixture of low-molecular-weight peptides and amino acids derived from porcine brain tissue. It is marketed in some countries for neurological uses but has no FDA-approved U.S. product or indication.
Acute-stroke evidence does not establish benefit
A 2023 Cochrane review of seven randomized trials involving 1,773 participants concluded that Cerebrolysin probably has little or no effect on death after acute ischemic stroke and probably increases nonfatal serious adverse events.[1] In the large CASTA randomized trial, the primary outcome did not differ significantly from placebo.[2]
Other small studies and pooled analyses have reported signals in stroke recovery, traumatic brain injury, or dementia, but differences in condition, timing, co-treatment, endpoints, and study quality prevent a general claim that Cerebrolysin repairs the brain or improves cognition.
Safety is not benign
Beyond the serious-adverse-event signal in acute stroke, a 2024 case report documented life-threatening anaphylaxis after intravenous Cerebrolysin.[3] A heterogeneous biological mixture also raises product-specific manufacturing and immunogenicity questions. Foreign labeling and local medical practice cannot be converted into self-injection instructions.
U.S. regulatory status
FDA has stated in a warning letter that Cerebrolysin is not a component of an FDA-approved drug.[4] Approval or sale in another country does not equal U.S. approval. Teloryx does not publish a Cerebrolysin infusion dose, cycle, or administration protocol.